Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06103500
Other study ID # 20230322-01T
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2024
Est. completion date March 31, 2025

Study information

Verified date April 2024
Source Ottawa Hospital Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As antibiotic resistance increases globally, it becomes more difficult to select empiric antibiotic therapy, particularly in patients with sepsis who stand to benefit from early adequate treatment. In particular it is difficult for clinicians to balance antibiotic stewardship principles (the need to avoid unnecessary prescribing of antibiotics that have an excessively broad spectrum of activity that favour resistance development) and under treatment. The integration of multiple risk variables for resistance are hard for clinicians to translate into clinical action, and is seemingly at odds with the natural inclination to provide heuristic/emotion-based antibiotic selection. The inappropriate treatment of sepsis is not uniformly too broad, or too narrow, and there is a need to optimize and tailor selection of antibiotic therapy to each patient, such that those that are at risk for resistant organisms receive broad therapy, and those that are not at risk, receive narrower antibiotic agents. Clinicians need support picking the right antibiotic for each patient, and from this they can potentially drive reduction of unnecessarily broad antibiotic prescribing while preserving adequacy of treatment. Individualized clinical prediction models and decision support interventions are promising approaches that meet these needs by improving the classification of patient risk for antibiotic resistant or susceptible infections in sepsis. Unfortunately, few have been validated in the clinical setting and larger rigorous studies are needed to provide the evidence to support broader clinical adoption. The investigators will perform a cluster randomized cross-over trial of an individualized antibiotic prescribing decision support intervention for providers treating hospitalized patients with suspected sepsis. The aim of this trial is to determine whether a stewardship led clinical decision support intervention can improve antibiotic de-escalation in patients with sepsis while maintaining or improving adequacy of antibiotic coverage. This decision support intervention will be based on a combination of proven decision heuristics (for Gram-positive organisms) and modelled predicted susceptibilities (for Gram-negative organisms) that are individualized to the patient. The primary outcome will be the proportion of patients de-escalated from their initial empiric regimen within 48 hours.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1400
Est. completion date March 31, 2025
Est. primary completion date January 2, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Admitted 2. Age >18 years old 3. Newly started (within 24 hours of assessment for eligibility) on at least one of the following antibiotic(s): I. Vancomycin II. Linezolid III. Daptomycin IV. Cefazolin V. Cloxacillin VI. Ceftriaxone VII. Ceftazidime VIII. Piperacillin-Tazobactam IX. Meropenem (or Imipenem or Ertapenem) X. Ciprofloxacin (or Moxifloxacin or Levofloxacin) XI. Gentamicin (or Tobramycin). 4. Blood cultures ordered (within 12 hours before or after initiation of antibiotics). Exclusion Criteria: 1. Documented end-of-life (palliative) care. 2. Already enrolled in the trial. 3. Positive clinical culture results for the index infection already available prior to giving advice. 4. Receipt of antimicrobials (not chronic suppression) in the prior 24-72 hours.

Study Design


Intervention

Other:
Clinical Decision Support Algorithm for Empiric Antibiotics in Sepsis
A clinical decision support algorithm for empiric antibiotic selection in suspected infection.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute Canadian Institutes of Health Research (CIHR)

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients De-escalated De-escalation from empiric antibiotic regimen within 48 hours of receipt of antibiotics [Binary]. 48 hours
Secondary Time to adequate therapy Time to adequate therapy for patients with positive blood cultures (hours from time of blood culture collection to first dose of agent(s) active against all pathogen(s) in the positive culture). 0-7 days
Secondary Number of Patients Receiving Adequate Therapy at 48 hours Receipt of adequate antibiotic therapy within 48 hours from blood culture collection for patients with positive cultures. 48 hours
Secondary Mortality In-hospital mortality, during index admission, and within 90 days of index event. 90 days
Secondary Length of stay Hospital length of stay on index admission (days). 0-90 days
Secondary De-escalation extent Extent of antibiotic de-escalation (ordinal value up or down the de-escalation cascade) 48 hours
Secondary Antibiotic spectrum at completion Antibiotic spectrum ranking on the last day of antibiotic treatment. Completion of therapy, up to 90 days
Secondary C.difficile Infection Positive stool testing for C. difficile during index admission, and within 90 days of index. 90 days
Secondary Dialysis New requirement for dialysis during index admission, and within 90 days of index. 90 days
Secondary Days of antibiotic therapy Total antibiotic days of therapy (DOT) during index admission, including by spectrum-level. End of index admission, up to 90 days
Secondary Escalation Newly started Gram-positive or Gram-negative coverage, or increases in spectrum of antibiotic therapy, as part of the intervention recommendation. 48hrs
Secondary Recommended change in Gram-negative coverage Recommended change in antibiotic therapy by Gram-negative model. At time of assessment
Secondary Accepted change in Gram-negative coverage Recommended change in antibiotic therapy by Gram-negative model was accepted and ordered. At time of assessment
Secondary Recommended change in Gram-positive coverage Recommended change in antibiotic therapy by Gram-positive algorithm. at time of assessment
Secondary Accepted change in Gram-positive coverage Recommended change in antibiotic therapy by Gram-positive algorithm was accepted and ordered. At 48 hrs
Secondary Non-recommended escalation at 7 days Escalation of antibiotic therapy (apart from recommended escalation) within 7 days of receipt of initial antibiotics 7 days
Secondary ICU admit or mortality ICU admission or death at 7 days from receipt of initial antibiotics 7 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3